AIM: To elucidate surgical outcomes of pancreaticoduodenectomy (PD) in patients with liver cirrhosis. METHODS: We studied retrospectively all patients who underwent PD in our centre between January 2002 and December 2011. Group A comprised patients with cirrhotic livers, and Group B comprised patients with non-cirrhotic livers. The cirrhotic patients had Child-Pugh classes A and B (patient's score less than 8). Preoperative demographic data, intra-operative data and postoperative details were collected. The primary outcome measure was hospital mortality rate. Secondary outcomes analysed included duration of the operation, postoperative hospital stay, postoperative morbidity and survival rate. RESULTS: Only 67/442 patients (15.2%) had cirrhotic livers. Intraoperative blood loss and blood transfusion were significantly higher in group A (P = 0.0001). The mean surgical time in group A was significantly longer than that in group B (P = 0.0001). Wound complications (P = 0.02), internal haemorrhage (P = 0.05), pancreatic fistula (P = 0.02) and hospital mortality (P = 0.0001) were significantly higher in the cirrhotic patients. Postoperative stay was significantly longer in group A (P = 0.03). The median survival was 19 mo in group A and 24 mo in group B. Portal hypertension (PHT) was present in 16/67 cases of cirrhosis (23.9%). The intraoperative blood loss and blood transfusion were significantly higher in patients with PHT (P = 0.001). Postoperative morbidity (0.07) and hospital mortality (P = 0.007) were higher in cirrhotic patients with PHT. CONCLUSION: Patients with periampullary tumours and well-compensated chronic liver disease should be routinely considered for PD at high volume centres with available expertise to manage liver cirrhosis. PD is associated with an increased risk of postoperative morbidity in patients with liver cirrhosis; therefore, it is only recommended in patients with Child A cirrhosis without portal hypertension.
AIM: To elucidate surgical outcomes of pancreaticoduodenectomy (PD) in patients with liver cirrhosis. METHODS: We studied retrospectively all patients who underwent PD in our centre between January 2002 and December 2011. Group A comprised patients with cirrhotic livers, and Group B comprised patients with non-cirrhotic livers. The cirrhotic patients had Child-Pugh classes A and B (patient's score less than 8). Preoperative demographic data, intra-operative data and postoperative details were collected. The primary outcome measure was hospital mortality rate. Secondary outcomes analysed included duration of the operation, postoperative hospital stay, postoperative morbidity and survival rate. RESULTS: Only 67/442 patients (15.2%) had cirrhotic livers. Intraoperative blood loss and blood transfusion were significantly higher in group A (P = 0.0001). The mean surgical time in group A was significantly longer than that in group B (P = 0.0001). Wound complications (P = 0.02), internal haemorrhage (P = 0.05), pancreatic fistula (P = 0.02) and hospital mortality (P = 0.0001) were significantly higher in the cirrhotic patients. Postoperative stay was significantly longer in group A (P = 0.03). The median survival was 19 mo in group A and 24 mo in group B. Portal hypertension (PHT) was present in 16/67 cases of cirrhosis (23.9%). The intraoperative blood loss and blood transfusion were significantly higher in patients with PHT (P = 0.001). Postoperative morbidity (0.07) and hospital mortality (P = 0.007) were higher in cirrhotic patients with PHT. CONCLUSION:Patients with periampullary tumours and well-compensated chronic liver disease should be routinely considered for PD at high volume centres with available expertise to manage liver cirrhosis. PD is associated with an increased risk of postoperative morbidity in patients with liver cirrhosis; therefore, it is only recommended in patients with Child A cirrhosis without portal hypertension.
Authors: Jordan M Winter; John L Cameron; Kurtis A Campbell; David C Chang; Taylor S Riall; Richard D Schulick; Michael A Choti; JoAnn Coleman; Mary B Hodgin; Patricia K Sauter; Christopher J Sonnenday; Christopher L Wolfgang; Michael R Marohn; Charles J Yeo Journal: J Gastrointest Surg Date: 2006-11 Impact factor: 3.452
Authors: Margijske H G van Roest; Annette S H Gouw; Paul M J G Peeters; Robert J Porte; Maarten J H Slooff; Vaclav Fidler; Koert P de Jong Journal: Ann Surg Date: 2008-07 Impact factor: 12.969
Authors: Shu You Peng; Jian Wei Wang; Wan Yee Lau; Xiu Jun Cai; Yi Ping Mou; Ying Bin Liu; Jiang Tao Li Journal: Ann Surg Date: 2007-05 Impact factor: 12.969
Authors: O Fathy; M Abdel M Wahab; N Elghwalby; A Sultan; G EL-Ebidy; N GadEl Hak; M Abu Zeid; T Abd-Allah; M El-Shobary; A Fouad; Th Kandeel; A Abo Elenien; A Abd El-Raouf; E Hamdy; A M Sultan; E Hamdy; Farouk Ezzat Journal: Hepatogastroenterology Date: 2008 May-Jun
Authors: Alessandro Cucchetti; Giorgio Ercolani; Marco Vivarelli; Matteo Cescon; Matteo Ravaioli; Giovanni Ramacciato; Gian Luca Grazi; Antonio Daniele Pinna Journal: Ann Surg Date: 2009-12 Impact factor: 12.969
Authors: Mohamed Abd ElWahab; Ayman El Nakeeb; Ehab El Hanafy; Ahmad M Sultan; Ahmed Elghawalby; Waleed Askr; Mahmoud Ali; Mohamed Abd El Gawad; Tarek Salah Journal: World J Gastrointest Surg Date: 2016-06-27
Authors: Kira L Newman; Kay M Johnson; Paul B Cornia; Peter Wu; Kamal Itani; George N Ioannou Journal: Clin Gastroenterol Hepatol Date: 2019-07-31 Impact factor: 11.382
Authors: Salman A A Jabbar; Nigel B Jamieson; Andrew J Morris; Karin A Oien; Fraser Duthie; Colin J McKay; Christopher R Carter; Euan J Dickson Journal: J Surg Case Rep Date: 2016-05-13
Authors: Zachary M Saleh; Quintin P Solano; Jeremy Louissaint; Peter Jepsen; Elliot B Tapper Journal: United European Gastroenterol J Date: 2021-06-08 Impact factor: 4.623
Authors: Giuseppe Maria Ettorre; Giovanni Battista Levi Sandri; Marco Colasanti; Edoardo de Werra; Pasquale Lepiane Journal: Ann Hepatobiliary Pancreat Surg Date: 2017-05-23